Related Experiment Video
Updated: Jul 11, 2026
11:36
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
[Immunization guidelines in patients with chronic liver diseases]
Florian Bihl1, Antoine Hadengue, Claire-Anne Siegrist
1Service de gastroentérologie et hépatologie, HUG, 1211 Genève 14.
Revue Medicale Suisse
|October 9, 2007
Summary
Patients with chronic liver diseases have weakened immune systems, increasing infection risk. Vaccinations are recommended, but efficacy varies, necessitating antibody level checks after boosters.
Area of Science:
- Immunology
- Hepatology
- Infectious Diseases
Context:
- Chronic liver disease, particularly cirrhosis, compromises immune function.
- Patients with chronic liver disease are susceptible to viral infections like hepatitis A and B.
- Vaccine efficacy in end-stage liver disease and transplant patients is often suboptimal.
Purpose:
- To highlight the vulnerability of patients with chronic liver disease to infections.
- To recommend vaccinations against hepatitis A and B viruses (HAV, HBV), influenza, and pneumococci for these patients.
- To address the reduced efficacy of vaccinations in advanced liver disease and post-transplant scenarios.
Summary:
- Patients with chronic liver disease exhibit impaired immunity, making them prone to viral coinfections.
- While vaccination against hepatitis A and B (HAV, HBV), flu, and pneumococci is advised upon diagnosis, reduced seroconversion rates are observed in advanced stages.
- Post-vaccination antibody level monitoring is crucial, especially after booster doses, to ensure adequate protection.
Impact:
- Emphasizes the need for tailored vaccination strategies in immunocompromised liver disease patients.
- Underscores the importance of monitoring immune response to vaccinations in this vulnerable population.
- Aims to improve preventive care and reduce infectious complications in individuals with chronic liver conditions.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...